ELIXA Trial

The ELIXA trial assessed CV safety associated with lixisenatide versus placebo in >6000 patients with T2D and a recent acute coronary syndrome. 3 This module details the CV outcomes and safety results from the trial.

ELIXA Trial
Rate this content
  • ELIXA Trial
  • ELIXA: study design
  • ELIXA: baseline characteristics (1/2)
  • ELIXA: baseline characteristics (2/2)
  • ELIXA: renal function at baseline
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go